Eugia Pharma Receives USFDA Approval for Methylprednisolone Acetate Injectable Suspension USP, 400 mg/10 mL (40 mg/mL) & 400 mg/5 mL (80 mg/mL) [Multi Dose Vial]

Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Methylprednisolone Acetate Injectable Suspension USP, 400 mg/10 mL (40 mg/mL) & 400 mg/5 mL (80 mg/mL) [Multi Dose Vial]

Indications for this product include:

For Intramuscular Administration:

• Allergic States
• Dermatologic Diseases
• Endocrine Disorders
• Gastrointestinal Diseases
• Hematologic Disorders
• Trichinosis with neurologic or myocardial involvement,
• Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
• Neoplastic Diseases
• Nervous System: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
• Ophthalmic Diseases
• Renal Diseases
• Respiratory Diseases
• Rheumatic Disorders

Refer to package insert for full prescribing information.